Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Hippocampus. 2018 Feb 12;28(4):251–268. doi: 10.1002/hipo.22832

Figure 3.

Figure 3

Expression levels impacted by perinatal MCS in ~11 MO MCS-treated offspring included select AD and DS response genes. A. Adam10 is upregulated 1.52 fold (2N versus Ts) in Ts65Dn mice and downregulated in Ts+ mice (Ts+ versus Ts) to 2N levels by MCS. B. Dyrk1a is upregulated 1.30 fold (2N versus Ts) in Ts65Dn mice and downregulated in Ts+ mice relative to 2N and Ts levels by MCS treatment, while Dyrk1a levels in Ts+ are not significantly different from 2N+ levels. C. Eif2ak2 is upregulated 1.35 fold (2N versus Ts) in Ts65Dn mice and downregulated in Ts+ mice (Ts+ versus Ts) to 2N levels by MCS. D. Mapk13 is upregulated 1.22 fold (2N versus Ts) in Ts65Dn mice and downregulated in Ts+ mice relative to 2N and Ts levels by MCS treatment, while Mapk13 levels in Ts+ are not significantly different from 2N+ levels. E. Apbb1 is downregulated 1.64 fold (2N versus Ts) in Ts65Dn mice and upregulated in Ts+ mice (Ts+ versus Ts) to 2N levels by MCS. F. Bace1 is downregulated 1.92 fold (2N versus Ts) in Ts65Dn mice and upregulated in Ts+ mice (Ts+ versus Ts) to 2N levels by MCS. G. Casp8 is downregulated 1.58 fold (2N versus Ts) in Ts65Dn mice and upregulated in Ts+ mice (Ts+ versus Ts) to 2N levels by MCS. H. Mapt2N6D is downregulated 1.87 fold (2N versus Ts) in Ts65Dn mice and upregulated in Ts+ mice (Ts+ versus Ts) to 2N levels by MCS. I. Mapt2N6P is downregulated 2.12 fold (2N versus Ts) in Ts65Dn mice and upregulated in Ts+ mice (Ts+ versus Ts) to significantly higher levels than Mapt2N6P expression in 2N and 2N+ mice. Key: *, p<0.01; **, p<0.005; ***, p<0.001. Upward arrowhead, significant upregulation; downward arrowhead, significant downregulation.